Iris Grossman
Durham University
46 Papers
266 Citations
Iris Grossman is an academic researcher from Durham University. The author has contributed to research in topics: Medicine & Pharmacogenetics. The author has an hindex of 21, co-authored 46 publications. Previous affiliations of Iris Grossman include Research Triangle Park & Duke University.
Chat about Author
Papers
Drug repurposing from the perspective of pharmaceutical companies.
Yoonjeong Cha,T Erez,Ian J. Reynolds,D Kumar,Jermaine Ross,Grigoriy Koytiger,Rebecca Kusko,Benjamin Zeskind,S Risso,E Kagan,S Papapetropoulos,Iris Grossman,Daphna Laifenfeld +12 more
TL;DR: Some of the main approaches to systematic repurposing are described and the various players in this field are discussed and the need for strategic collaborations to increase the likelihood of success in bringing existing molecules to new indications is discussed.
359
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor
Joel Kaye,Victor Piryatinsky,Tal Birnberg,Tal Hingaly,Emanuel Raymond,Rina Kashi,Einat Amit-Romach,Ignacio S. Caballero,Fadi Towfic,Mark A. Ator,Efrat Rubinstein,Daphna Laifenfeld,Aric Orbach,Doron Shinar,Yael Marantz,Iris Grossman,Volker Knappertz,Michael R. Hayden,Ralph Laufer +18 more
TL;DR: The consequences of AhR activation in myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) using AhR knockout mice are tested and it is demonstrated that the pronounced effect of laquinimod on clinical score, CNS inflammation, and demyelination in EAE was abolished in AhR−/− mice.
122
The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.
Daniel A. Ryskamp,Jun Wu,Michal Geva,Rebecca Kusko,Iris Grossman,Michael R. Hayden,Ilya Bezprozvanny +6 more
TL;DR: It is reported here that pridopidine and the chemically similar S1R agonist 3-PPP prevent MSN spine loss in aging YAC128 co-cultures and highlights S 1R as a potential target for HD therapy.
111
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.
Anna C. Need,Richard S.E. Keefe,Dongliang Ge,Iris Grossman,Iris Grossman,Samuel P. Dickson,Samuel P. Dickson,Joseph P. McEvoy,David Goldstein +8 more
TL;DR: The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Phase 1 Schizophrenia trial compared the effectiveness of one typical and four atypical antipsychotic medications as mentioned in this paper.
Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs)
David B. Matchar,Mugdha Thakur,Iris Grossman,Douglas C McCrory,Lori A. Orlando,David C. Steffens,David Goldstein,Kathryn E Cline,Rebecca Gray +8 more
- 01 Jan 2007
TL;DR: There is a paucity of good-quality data addressing the questions of whether testing for CYP450 polymorphisms in adults entering SSRI treatment for non-psychotic depression leads to improvement in outcomes, or whether testing results are useful in medical, personal, or public health decisionmaking.
82